What is the 13F Pro Quality Score for SRPT?

13F Pro ranks Sarepta Therapeutics, Inc. (SRPT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SRPT's current score at https://13fpro.ai/research/SRPT (free sign-up required for the full ranking).

Which hedge funds own the most SRPT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SRPT include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SRPT as soon as new 13F filings post.

Where does 13F Pro source SRPT data?

All Sarepta Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Sarepta Therapeutics, Inc. files with the SEC under CIK 873303. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SRPT in?

Sarepta Therapeutics, Inc. (SRPT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SRPT research updated on 13F Pro?

SRPT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Sarepta Therapeutics, Inc.(SRPT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 873303 SRPT stock profile & AI dashboard →

13F Pro Quality Score

41.6/100

Rank #1,884 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

85.7/100

Profitability

22.2/100

Balance Sheet

27.5/100

Earnings Quality

30.0/100

Free Cash Flow

11.0/100

Institutional Flow

48.6/100

Revenue Scale

60.9/100

Dilution Risk

24.1/100

SRPT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Sarepta Therapeutics, Inc. (SRPT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SRPT at 41.6/100 on a 32-signal composite quality model, placing it at rank #1,884 of 2,879 stocks — the bottom half of the AI-ranked universe. SRPT scores in the top quartile across revenue growth (85.7). Areas of concern include free cash flow (11.0) and profitability (22.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Sarepta Therapeutics, Inc. reports quarterly revenue of $730.8M, net income of $331.0M, free cash flow of $-204.8M. Top institutional holders of SRPT by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, STATE STREET, based on the most recent SEC filings. SRPT trades on the Nasdaq exchange and files with the SEC under CIK 873303. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SRPT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sarepta Therapeutics, Inc. directly from SEC EDGAR. Sarepta Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 8 and 58 since 2021, currently 41.6 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Sarepta Therapeutics, Inc.

Quirks, history, and lore behind SRPT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · mid-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the range of roughly $1 billion, built almost entirely on a single rare disease franchise — blockbuster or bust.
3
The History
Founded in the early 1980s and spent decades as a scrappy biotech before pivoting hard into genetic medicine for devastating muscle-wasting diseases.
4
The Secret
Its signature strategy is exon skipping — a molecular trick that instructs the body to skip over a broken section of genetic code, like editing a typo out of a very important sentence.
5
The Lore
Its FDA approval pathway was one of the most contested in agency history, sparking fierce debate over accelerated approval for rare pediatric diseases — patients and scientists publicly clashed over the data.
6
The Giveaway
This company makes Elevidys, the first gene therapy approved for Duchenne muscular dystrophy — a disease that robs boys of their ability to walk, and whose families fought for this drug for decades.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$730.8M

Net Income

Q1 2026

$331.0M

Free Cash Flow

Q1 2026

$-204.8M

D/E Ratio

Q1 2026

0.56

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+76.8% YoY

$2.20BFY 2025

FY19 $380.8MFY20 $540.1MFY23 $1.24BFY25 $2.20B

Net Income

-33.1% YoY

$-713.4MFY 2025

FY19 $-715.1MFY20 $-554.1MFY23 $-536.0MFY25 $-713.4M

Operating Income

-161.3% YoY

$-699.8MFY 2025

FY19 $-705.6MFY20 $-564.2MFY23 $-267.8MFY25 $-699.8M

EPS (Diluted)

-22.9% YoY

$-7.13FY 2025

FY19 —FY20 $-7.11FY23 $-5.80FY25 $-7.13

Total Assets

+2.6% YoY

$3.35BFY 2025

FY19 $1.82BFY20 $2.98BFY23 $3.26BFY25 $3.35B

Total Debt

-38.3% YoY

$829.0MFY 2025

FY19 —FY20 —FY23 $1.34BFY25 $829.0M

Op. Cash Flow

+59.0% YoY

$-205.5MFY 2025

FY19 $-456.5MFY20 $107.5MFY23 $-501.0MFY25 $-205.5M

Metric	FY 2025	FY 2023	FY 2020	FY 2019	FY 2018	FY 2016
Revenue	$2.20B +76.8%	$1.24B +130.2%	$540.1M +41.8%	$380.8M +26.5%	$301.0M +5453.1%	$5.4M
Net Income	$-713.4M -33.1%	$-536.0M +3.3%	$-554.1M +22.5%	$-715.1M -97.6%	$-361.9M -35.4%	$-267.3M
Operating Income	$-699.8M -161.3%	$-267.8M +52.5%	$-564.2M +20.0%	$-705.6M -105.3%	$-343.6M -28.8%	$-266.7M
EPS (Diluted)	$-7.13 -22.9%	$-5.80 +18.4%	$-7.11	—	—	—
Total Assets	$3.35B +2.6%	$3.26B +9.4%	$2.98B +63.7%	$1.82B +11.0%	$1.64B +287.2%	$424.1M
Total Debt	$829.0M -38.3%	$1.34B	—	—	$420.6M +2280.3%	$17.7M
Operating Cash Flow	$-205.5M +59.0%	$-501.0M -566.2%	$107.5M +123.5%	$-456.5M -17.4%	$-388.7M -58.1%	$-245.8M

AI Insight: SRPT Financial Trends

Sarepta swung to Q1 2026 profitability with $358M operating income, but operating cash flow turned negative despite debt reduction.

• Operating income rebounded to $358M in Q1 2026 from $-412M in Q4 2025, a $770M swing.

• Total debt fell to $838M in Q1 2026 from $1,318M in Q2 2024, reducing leverage by 36%.

• Revenue volatile: $731M in Q1 2026 vs. $443M in Q4 2025, but well below $745M peak in Q1 2025.

⚠ Operating cash flow turned negative $203M in Q1 2026 despite $358M operating income—working capital or timing issue.

⚠ Net income swung wildly: $331M in Q1 2026 vs. $-283M in Q4 2025. Earnings quality and sustainability unclear.

AI Insight: SRPT Ratio Trends

Sarepta rebounded sharply in Q1 2026 with operating margin of 49.0% and ROIC of 61.2%, reversing four consecutive quarters of losses.

• Operating margin surged to 49.0% in Q1 2026 from -92.9% in Q4 2025; NPM improved to 45.3% from -63.9%.

• ROIC recovered to 61.2% in Q1 2026 versus -83.6% in Q4 2025; ROE climbed to 88.0% from -99.2%.

• Debt-to-equity decreased to 0.56 in Q1 2026, lowest since Q2 2024 (1.22), signaling deleveraging.

⚠ Extreme volatility: five of past eight quarters show negative margins or ROIC; Q1 2026 recovery must prove sustainable.

⚠ TTM margins remain weak (OpMargin -1.9%, NPM 3.0%) despite Q1 2026 strength, indicating recent quarters dragged results.

Get alerted when SRPT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Sarepta Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SRPT

BlackRock, Inc.
$321.1M14,755,277 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$144.5M6,640,692 sh
STATE STREET CORP
$143.9M6,613,314 sh
AQR CAPITAL MANAGEMENT LLC
$138.6M6,433,112 sh
TWO SIGMA INVESTMENTS, LP
$99.9M4,593,195 sh
VANGUARD CAPITAL MANAGEMENT LLC
$99.6M4,578,235 sh
FIRST TRUST ADVISORS LP
$90.0M4,135,788 sh
RA CAPITAL MANAGEMENT, L.P.
$84.9M3,902,596 sh
Erste Asset Management GmbH
$61.3M2,968,945 sh
MORGAN STANLEY
$56.5M2,596,993 sh

Fund	Value	Shares
BlackRock, Inc.	$321.1M	14,755,277
VANGUARD PORTFOLIO MANAGEMENT LLC	$144.5M	6,640,692
STATE STREET CORP	$143.9M	6,613,314
AQR CAPITAL MANAGEMENT LLC	$138.6M	6,433,112
TWO SIGMA INVESTMENTS, LP	$99.9M	4,593,195
VANGUARD CAPITAL MANAGEMENT LLC	$99.6M	4,578,235
FIRST TRUST ADVISORS LP	$90.0M	4,135,788
RA CAPITAL MANAGEMENT, L.P.	$84.9M	3,902,596
Erste Asset Management GmbH	$61.3M	2,968,945
MORGAN STANLEY	$56.5M	2,596,993

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SRPT on your watchlist

Track score changes the day Sarepta Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SRPT a good stock to buy?

13F Pro's AI-powered analysis of Sarepta Therapeutics, Inc. (SRPT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SRPT are available on the SRPT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SRPT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SRPT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sarepta Therapeutics, Inc.'s investment landscape.